SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Spatial lipidomics identifies α-synuclein-induced lipid changes in an AAV-induced Parkinsonian mouse model.

Neurobiol Dis · 2026-03-31

DOI: 10.1016/j.nbd.2026.107372PMID: 41933666

Check source for accessJournal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Parkinson's disease (PD) is characterized by Lewy body pathology, mainly consisting of accumulation of aggregated α-synuclein and lipid contents. Lipid dyshomeostasis has frequently been observed in PD, and compelling evidences indicate that lipids play critical roles in modulating α-synuclein toxicity. However, how α-synuclein regulates brain lipid composition remains poorly understood. Here, we used dual polarity matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to spatially profile brain lipids in a unilateral adeno-associated virus (AAV)-α-synuclein mouse model of Parkinsonism. We identified region-specific alterations in sphingolipids and glycerophospholipids in the substantia nigra and striatum of these mice. In sphingolipids, α-synuclein overexpression altered certain monosialotetrahexosylgangliosides (GM1s), sphingomyelins (SMs), and sulfated hexosyl ceramides (SHexCers; a.k.a. sulfatides). Glycerophospholipid changes followed a desaturation pattern: polyunsaturated fatty acid (PUFA)-containing species were decreased, while saturated and mono-unsaturated species were increased. Additionally, oxidized phosphatidylcholine (PC) lipids, such as SAzPC (1-stearoyl-2-azelaoyl-sn-PC) and PAzPC(1-palmitoyl-2-azelaoyl-sn-PC), were elevated in the substantia nigra, and ether phosphatidylethanolamines (PEs) were reduced in the substantia nigra but increased in the striatum. Our study provides a comprehensive, spatially resolved lipidomic landscape of α-synuclein-induced pathology in the nigrostriatal pathway, offering new insights into lipid dysregulation in experimental PD and a framework for future therapeutic exploration.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.